Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry
暂无分享,去创建一个
Gerd Mikus | Walter E Haefeli | W. Haefeli | G. Mikus | J. Burhenne | Jürgen Burhenne | K. Riedel | Klaus-Dieter Riedel | Birte Halama | Monika Maurer | Nicolas Hohmann | N. Hohmann | B. Halama | M. Maurer
[1] Li Li,et al. Development and validation of a LC-MS/MS method based on a new 96-well Hybrid-SPE™-precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma , 2011, Analytical and bioanalytical chemistry.
[2] W. Haefeli,et al. Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy , 2011, Clinical pharmacology and therapeutics.
[3] A. McLachlan,et al. A High-Throughput Assay Using Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous In Vivo Phenotyping of 5 Major Cytochrome P450 Enzymes in Patients , 2009, Therapeutic drug monitoring.
[4] D. Breimer,et al. A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. , 1990, Trends in pharmacological sciences.
[5] Honghui Zhou,et al. “Cocktail” Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science? , 2004, Journal of clinical pharmacology.
[6] F. Akhlaghi,et al. Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[7] T. Annesley. Ion suppression in mass spectrometry. , 2003, Clinical chemistry.
[8] Elizabeth Landrum Michalets,et al. Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.
[9] F Peter Guengerich,et al. Cytochromes P450, drugs, and diseases. , 2003, Molecular interventions.
[10] K. Verbeke,et al. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. , 2011, Biomedical chromatography : BMC.
[11] X. Boulenc,et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. , 2009, British journal of clinical pharmacology.
[12] T. Olah,et al. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. , 1999, Rapid communications in mass spectrometry : RCM.
[13] Nicholas B Tiscione,et al. Quantitation of benzodiazepines in whole blood by electron impact-gas chromatography-mass spectrometry. , 2008, Journal of analytical toxicology.
[14] K. Linnet,et al. A validated method for simultaneous screening and quantification of twenty-three benzodiazepines and metabolites plus zopiclone and zaleplone in whole blood by liquid-liquid extraction and ultra-performance liquid chromatography- tandem mass spectrometry. , 2010, Journal of analytical toxicology.
[15] Wei Zhang,et al. Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[16] S. Lutz-Bonengel,et al. Cocktail Approach for In Vivo Phenotyping of 5 Major CYP450 Isoenzymes: Development of an Effective Sampling, Extraction, and Analytical Procedure and Pilot Study With Comparative Genotyping , 2012, Journal of clinical pharmacology.
[17] F. Tse,et al. Simultaneous determination of midazolam and 1'-hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.
[18] L. Bertilsson,et al. The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes , 2003, Clinical pharmacology and therapeutics.
[19] E. Sellers,et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail” , 2003, Clinical pharmacology and therapeutics.
[20] S. Athanaselis,et al. Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. , 2010, Journal of pharmaceutical and biomedical analysis.
[21] D. Greenblatt,et al. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. , 2009, British journal of clinical pharmacology.
[22] H. Kokki,et al. Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[23] G. McMillin,et al. Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS. , 2008, Journal of analytical toxicology.
[24] S. Krähenbühl,et al. Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.
[25] M. H. Ensom,et al. Clinical Pharmacokinetic Monitoring of Midazolam in Critically Ill Patients , 2007, Pharmacotherapy.
[26] Malcolm Rowland,et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.
[27] B. Matuszewski,et al. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.